HRT With Uterus Intact: What Every Woman Needs to Know

Why a Uterus Changes Everything About HRT

Women who still have their uterus cannot safely take estrogen alone. The endometrium, the lining of the uterus, responds to estrogen by proliferating. Without a progestogen to oppose that proliferation, the tissue can progress from hyperplasia to endometrial carcinoma over months to years. A landmark analysis published in the New England Journal of England confirmed that 10 or more years of unopposed estrogen raised endometrial cancer risk by approximately 10-fold compared to non-users [1]. Women who had a hysterectomy need only estrogen; women with an intact uterus always need estrogen plus a progestogen.

This single distinction divides all HRT prescribing into two branches. Get the branch wrong and you either deny a woman effective therapy (no estrogen at all) or expose her to a preventable cancer (estrogen without progestogen). The remainder of this article covers how to get it right.

The 2023 Menopause Society (formerly NAMS) position statement states explicitly: "For women with a uterus, systemic estrogen therapy should be accompanied by a progestogen to prevent endometrial hyperplasia and carcinoma." [2]

Sequential vs. Continuous Combined HRT: Choosing the Right Regimen

The two main combined regimens differ in how the progestogen is delivered, and the correct choice depends on menstrual status. Sequential HRT adds progestogen for 10 to 14 days per cycle, producing a scheduled withdrawal bleed. Continuous combined HRT provides progestogen every day, aiming for an atrophic endometrium with no bleeding.

Sequential HRT is the standard choice for perimenopausal women and those who have been postmenopausal for fewer than 12 months. Because these women still have residual cyclical estrogen fluctuation, prescribing daily progestogen can cause erratic bleeding that is clinically confusing and often misinterpreted as breakthrough pathology. Monthly sequential therapy (progestogen for 12 to 14 days each calendar month) keeps the pattern predictable. Three-monthly (long-cycle) sequential therapy, using progestogen for 14 days every 13 weeks, reduces the number of bleeds to four per year, but evidence from a 2009 Cochrane review found it carries a slightly higher rate of endometrial hyperplasia than monthly sequential regimens, so endometrial surveillance may be warranted in women using long-cycle schedules for more than 12 months [3].

Continuous combined HRT suits women who are clearly postmenopausal (more than 12 consecutive months since last natural period) and who want to avoid monthly bleeds. The Women's Health Initiative (WHI) trial used conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg daily. In the combined-HRT arm (N = 16,608), the endometrial cancer hazard ratio was 0.83 (95% CI 0.47 to 1.47) compared to placebo, confirming endometrial protection [4]. Any unscheduled bleeding during continuous combined therapy requires prompt investigation to rule out endometrial pathology.

Progestogen Options: Micronized Progesterone vs. Synthetic Progestins

Not all progestogens carry identical risk profiles. Choosing wisely matters particularly for breast cancer risk and cardiovascular tolerance. The main options are oral micronized progesterone (OMP, sold as Prometrium or Utrogestan), the levonorgestrel-releasing IUS (Mirena 52 mg), and synthetic progestins such as medroxyprogesterone acetate (MPA), norethisterone acetate (NETA), and dydrogesterone.

Oral micronized progesterone is bioidentical to endogenous progesterone. The E3N French cohort study (N = 80,377 women followed for a mean of 8.1 years) found that combined HRT using estradiol plus OMP was not associated with a statistically significant increase in breast cancer risk (RR 1.00 to 95% CI 0.83 to 1.22), whereas estradiol combined with synthetic progestins carried a significantly elevated risk (RR 1.69 for norpregnane derivatives) [5]. These observational data informed the shift in European and North American guidelines toward preferring OMP when available.

The levonorgestrel IUS (Mirena 52 mg) delivers progestogen locally to the endometrium with minimal systemic absorption. The British Menopause Society accepts the 52 mg levonorgestrel IUS as a licensed method of endometrial protection for women using systemic estrogen HRT, provided the IUS is replaced every five years [6]. Women who find oral progesterone sedating (OMP has a mild sedative effect at the 200 mg dose) or who have poor gastrointestinal absorption may do better with the IUS route.

MPA remains widely prescribed but carries a higher risk profile. The WHI combined-HRT arm, which used MPA, showed a hazard ratio of 1.24 (95% CI 1.02 to 1.50) for invasive breast cancer after a mean 5.6 years [4]. Many clinicians now reserve MPA for women who cannot use OMP or the levonorgestrel IUS.

Dosing Schedules at a Glance

For monthly sequential HRT, a common regimen is transdermal estradiol 50 mcg/24 hours (patch or gel) applied continuously, with OMP 200 mg orally each night for days 1 to 14 of each calendar month. This produces a bleed around day 15 to 17.

For continuous combined HRT, transdermal estradiol 50 mcg/24 hours plus OMP 100 mg orally nightly is a frequently prescribed protocol. Dose adjustments are made at 8 to 12 weeks based on symptom control and side-effect profile.

Women with persistent vasomotor symptoms on 50 mcg transdermal estradiol may benefit from dose escalation to 75 or 100 mcg, with the progestogen dose scaled accordingly (OMP 200 mg nightly in sequential mode, or 100 mg nightly continuously). NICE NG23 advises against routine monitoring of hormone blood levels once a woman is on a stable dose and is symptom-controlled, but levels may help guide dose decisions when symptoms persist [7].

HRT in Perimenopause With an Intact Uterus

Perimenopause, typically spanning 2 to 8 years before the final menstrual period, produces erratic estrogen swings rather than the sustained low estrogen of full menopause. Vasomotor symptoms, sleep disruption, mood shifts, and irregular bleeding are common. Starting combined HRT during this window requires sequential rather than continuous progestogen.

The NICE NG23 guideline recommends offering HRT to perimenopausal women for troublesome vasomotor symptoms, noting that the benefits generally outweigh the risks for healthy women under 60 or within 10 years of menopause onset [7]. Women who are still having periods should start on a monthly sequential regimen. The progestogen-free phase mirrors the follicular phase of the natural cycle, and the progestogen phase induces a withdrawal bleed analogous to menstruation.

One practical complication: contraception. Perimenopause does not mean infertility. A woman who is still ovulating occasionally can conceive, and HRT is not a contraceptive. FSRH guidance recommends continuing contraception until age 55 in women who were over 50 at last natural period, or for 2 years after the last period in women under 50 [8]. The levonorgestrel IUS serves dual purposes here: endometrial protection for HRT and highly effective contraception (failure rate <0.1% per year).

HRT in Late Postmenopause With an Intact Uterus

Women who are several years past menopause may ask about starting HRT for the first time, either for persistent hot flashes, genitourinary syndrome of menopause (GSM), or osteoporosis prevention. The "timing hypothesis," supported by data from the Kronos Early Estrogen Prevention Study (KEEPS, N = 727) and the Danish Osteoporosis Prevention Study (DOPS, N = 1,006), suggests that cardiovascular benefits are greater when HRT starts close to menopause rather than a decade later [9].

Women starting HRT more than 10 years after menopause and over age 60 face a different risk-benefit calculation. The absolute cardiovascular and venous thromboembolism (VTE) risks are higher in this group. Transdermal estradiol bypasses first-pass hepatic metabolism and is associated with a lower VTE risk than oral estradiol in observational data, including the ESTHER case-control study (OR for VTE with transdermal estradiol: 0.9 to 95% CI 0.4 to 2.1, vs. OR 3.5 for oral estradiol) [10].

For this group, continuous combined HRT is appropriate if the woman is clearly postmenopausal, using the lowest effective estrogen dose and OMP or levonorgestrel IUS for endometrial protection.

HRT and PCOS: Special Considerations

Women with polycystic ovary syndrome (PCOS) approaching perimenopause present a distinct clinical picture. PCOS is associated with chronic low-grade estrogen exposure, often without regular progesterone opposition, because anovulatory cycles leave the endometrium exposed to estrogen for months at a time. This pre-existing endometrial exposure history raises baseline endometrial cancer risk independent of HRT.

The 2023 International Evidence-Based PCOS Guideline notes that women with PCOS have a 2.7-fold higher risk of endometrial cancer compared to the general population (relative risk 2.79 to 95% CI 1.31 to 5.95) [11]. For these women, any HRT regimen must include consistent and adequate progestogen coverage. Monthly sequential HRT may not provide enough progestogen days in women who were previously anovulatory for extended periods. Some clinicians prefer continuous combined HRT or the levonorgestrel IUS to maximize endometrial protection, even during perimenopause.

Insulin resistance, which is prevalent in PCOS, does not improve consistently with standard-dose HRT, so GLP-1 receptor agonists or metformin may need to run alongside HRT rather than being replaced by it. Androgen levels in PCOS may fall naturally at menopause, but testosterone replacement is occasionally considered for women with PCOS who report significant loss of libido after menopause, using evidence-based dosing from the Global Consensus Position Statement on testosterone for women [12].

Endometrial Monitoring: When to Investigate and When to Reassure

Unscheduled bleeding on HRT always requires investigation, but the threshold and approach differ by regimen type. On sequential HRT, bleeding that starts before day 11 of the progestogen phase, or that persists more than 6 days after the progestogen course ends, is considered irregular and warrants investigation per British Menopause Society guidance [6].

On continuous combined HRT, any bleeding after the first 6 months of therapy (or after a previously bleed-free period) needs pelvic ultrasound and usually endometrial biopsy. Endometrial thickness below 4 mm on transvaginal ultrasound has a negative predictive value for endometrial carcinoma of greater than 99% in postmenopausal women, according to a 2010 meta-analysis of 35 studies [13].

Women on the levonorgestrel IUS for endometrial protection frequently experience light irregular spotting during the first 3 to 6 months of IUS use. This typically settles. Spotting that persists beyond 6 months with the IUS in situ warrants transvaginal ultrasound to confirm endometrial thinning.

Breast Cancer Risk: Absolute Numbers in Context

The elevated breast cancer risk associated with combined HRT is real, but absolute numbers matter more than relative risk figures for shared decision-making. The WHI combined arm found 8 additional breast cancer cases per 10,000 women per year compared to placebo [4]. The Collaborative Group on Hormonal Factors in Breast Cancer (2019 meta-analysis, N = 108,647 breast cancer cases) found that 5 years of combined estrogen-progestogen HRT was associated with approximately 1 extra breast cancer case per 50 users over a 20-year period for women starting HRT at age 50 [14].

Risk varies substantially by progestogen type, as noted above. Women who use OMP or dydrogesterone carry a lower observed risk than those using MPA or NETA, though all estimates remain under scrutiny because the WHI data predated the widespread use of OMP.

Regular breast screening is recommended regardless of HRT use. In the UK, NHS Breast Screening invites women ages 50 to 71 every 3 years; HRT use does not change the screening interval, but women should inform their radiologist of current HRT type and duration.

Route of Administration: Patches, Gels, Sprays, and Oral Options

Estrogen can be delivered transdermally (patches, gels, sprays) or orally. Transdermal delivery maintains more stable serum estradiol levels and avoids the hepatic first-pass effect that raises clotting factors and sex hormone-binding globulin. For women with cardiovascular risk factors, migraine with aura, or a personal or family history of VTE, transdermal estradiol is the preferred route. Oral estradiol at standard doses is still appropriate for women with low cardiovascular risk and good hepatic function.

Progestogen can be delivered orally (OMP capsules taken at bedtime to minimize daytime sedation), vaginally (using OMP pessaries when the sedative effect is pronounced), or via the levonorgestrel IUS. Progestogen patches combined with estradiol in a single dual-hormone patch (such as Evorel Conti or Evorel Sequi in the UK) are convenient but limit the ability to independently titrate each hormone's dose.

Vaginal estrogen for GSM is safe to add to systemic combined HRT when local symptoms persist despite adequate systemic dosing. Vaginal estrogen at standard doses (e.g., estradiol 10 mcg vaginal tablets, Vagifem) does not require additional progestogen because systemic absorption is negligible [7].

Absolute and Relative Contraindications

Before starting combined HRT in a woman with an intact uterus, the following contraindications require assessment.

Absolute contraindications include: current or recent breast cancer, undiagnosed vaginal bleeding, confirmed or suspected endometrial cancer, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease (within the past 12 months), known estrogen-sensitive liver disease, and known thrombophilia without anticoagulation. Women with a BRCA1 or BRCA2 mutation who have not had a risk-reducing mastectomy should discuss HRT with a specialist in hereditary cancer.

Relative contraindications requiring case-by-case discussion include: personal history of VTE (transdermal estrogen substantially lowers but does not abolish risk), well-controlled hypertension (not a contraindication per se, but blood pressure should be monitored), and fibroids (estrogen may stimulate fibroid growth, causing increased bleeding; MRI surveillance may be appropriate in women with large fibroids starting HRT).

Endometriosis history is a specific consideration. Women with a history of endometriosis who have not had a hysterectomy should use continuous combined HRT rather than sequential therapy, because the monthly withdrawal bleed can reactivate endometriosis deposits.

Starting, Stopping, and Tapering HRT

Initiation should follow a baseline assessment that includes blood pressure, BMI, personal and family history of breast cancer, cardiovascular disease, VTE, and liver disease, plus a current breast screen and cervical screen if due. No specific blood tests are required to confirm menopause in women over 45 with typical symptoms per NICE NG23 [7]; FSH and estradiol measurements are unreliable during perimenopause due to cyclical variability.

After starting, follow up at 3 months to review symptom control, bleeding pattern, and tolerability. Many women need dose adjustments within the first 3 to 6 months. Steady-state symptom control typically occurs by 8 to 12 weeks on a stable dose.

Stopping HRT is not obligatory after any fixed duration for most healthy women under 60. The 2022 Menopause Society position statement and the British Menopause Society both advise that there is no arbitrary cut-off, and that duration should be guided by individual risk-benefit review, not a blanket 5-year or 10-year rule [2][6]. When a woman chooses to stop, gradual dose reduction over 3 to 6 months may reduce the likelihood of symptom rebound compared to abrupt cessation, though randomized data on tapering schedules remain limited.

Women stopping HRT after a long duration should be reminded that bone protection from HRT is lost within 2 to 5 years of stopping. If osteoporosis prevention was a key indication, a DEXA scan and consideration of alternative bone-protective agents (alendronate 70 mg weekly, denosumab 60 mg subcutaneously every 6 months) should occur at the time of HRT discontinuation.